This case report describes a 59-year-old man with myelin oligodendrocyte glycoprotein (MOG)-positive longitudinal extensive transverse myelitis (LETM) after being vaccinated with the COVID-19 vaccine ChAdOx1 nCoV-19. He presented with urinary retention, gait disturbance, hypoesthesia and brisk reflexes in his lower extremities without paresis. Due to the ineffectiveness of high-dose intravenous methylprednisolone, therapeutic plasma exchange was performed, gradually improving the patient’s condition. Vaccination as a trigger for an excessive immunological response seems plausible, though unspecific for the ChAdOx1 nCoV-19 vaccine.
Singh MalhotraHGuptaPPrabhuV, et al. COVID-19 vaccination-associated myelitis. QJM. Epub ahead of print 31 March 2021. DOI: 10.1093/qjmed/hcab069.
2.
PagenkopfCSudmeyerM. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol2021; 358: 577606.
3.
HemmerBBorsanyiC. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-SpektrumErkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie. Leitlinien für Diagnostik und Therapie in der Neurologie, 2021, www.dgn.org/leitlinien
4.
VoyseyMClemensSACMadhiSA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet2021; 397: 99–111.
5.
VegezziERavagliaSBuongarzoneG, et al. Acute myelitis and ChAdOx1 nCoV-19 vaccine: Casual or causal association?J Neuroimmunol2021; 359: 577686.
6.
RomanGCGraciaFTorresA, et al. Acute transverse myelitis (ATM): Clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol2021; 12: 653786.
7.
SriwastavaSTandonMPoduryS, et al. COVID-19 and neuroinflammation: A literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2. J Neurol. Epub ahead of print 19 May 2021. DOI: 10.1007/s00415-021-10611-9.
8.
JumahMRahmanFFiggieM, et al. COVID-19, HHV6 and MOG antibody: A perfect storm. J Neuroimmunol2021; 353: 577521.
9.
SinhaRWanderAKapoorA, et al. Acute demyelinating syndrome (MOG antibody positive) associated with COVID-19 infection: A widening spectrum. Clin Pediatr2021; 60: 501–503.
10.
KogureCKikushimaWFukudaY, et al. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case report. Medicine2021; 100: e25865.
11.
ZoricLRajovic-MrkicIColakE, et al. Optic neuritis in a patient with seropositive myelin oligodendrocyte glycoprotein antibody during the post-COVID-19 period. Int Med Case Rep J2021; 14: 349–355.
12.
PetersJAlhasanSVogelsCBF, et al. MOG-associated encephalitis following SARS-COV-2 infection. Mult Scler Relat Disord2021; 50: 102857.
13.
WoodhallMMitchellJWGibbonsE, et al. Case report: Myelin oligodendrocyte glycoprotein antibody-associated relapse with COVID-19. Front Neurol2020; 11: 598531.
14.
GargRKPaliwalVKGuptaA. Spinal cord involvement in COVID-19: A review. J Spinal Cord Med. Epub ahead of print 11 March 2021. DOI: 10.1080/10790268.2021.1888022.
15.
AmanoHMiyamotoNShimuraH, et al. Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: A case report. BMC Neurol2014; 14: 224.
16.
LoosJPfeufferSPapeK, et al. MOG encephalomyelitis: Distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. J Neurol2020; 267(6): 1632–1642.
17.
JariusSPaulFAktasO, et al. MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. J Neuroinflammation2018; 15: 134.
18.
WhittamDHCobo-CalvoALopez-ChiribogaAS, et al. Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Mult Scler Relat Disord2020; 44: 102251.
